Cargando…

Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands

Detalles Bibliográficos
Autores principales:	Slot, Stefanie, Dinmohamed, Avinash G., Visser, Otto, te Boekhorst, Peter A. W., Zweegman, Sonja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238331/ https://www.ncbi.nlm.nih.gov/pubmed/34235398 http://dx.doi.org/10.1097/HS9.0000000000000595

Ejemplares similares

Treatment and Survival of Patients With Primary Effusion Lymphoma in the Netherlands: A Population-based Analysis, 2002–2015
por: Dinmohamed, Avinash G., et al.
Publicado: (2018)

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018
por: Brink, Mirian, et al.
Publicado: (2021)

Relative survival in early-stage cancers in the Netherlands: a population-based study
por: Dinmohamed, Avinash G., et al.
Publicado: (2020)

Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
por: van der Meulen, Matthijs, et al.
Publicado: (2020)

Conditional relative survival in primary central nervous system lymphoma: a population-based study in the Netherlands
por: Dinmohamed, Avinash G, et al.
Publicado: (2020)

Primary therapy and survival among patients with nodular lymphocyte‐predominant Hodgkin lymphoma: a population‐based analysis in the Netherlands, 1993–2016
por: Posthuma, Hidde L. A., et al.
Publicado: (2019)

Conditional relative survival in Waldenström’s macroglobulinaemia: a population‐based study in The Netherlands
por: Amaador, Karima, et al.
Publicado: (2021)

Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018
por: Amaador, Karima, et al.
Publicado: (2021)

Conditional relative survival among patients with chronic lymphocytic leukaemia: A population‐based study in the Netherlands
por: van der Straten, Lina, et al.
Publicado: (2021)

Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands
por: Dinnessen, Manette A. W., et al.
Publicado: (2021)

Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018
por: Dinnessen, Manette A. W., et al.
Publicado: (2021)

Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands
por: Posthuma, Hidde L. A., et al.
Publicado: (2021)

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019
por: van der Straten, Lina, et al.
Publicado: (2023)

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
por: Brink, Mirian, et al.
Publicado: (2022)

Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018
por: Durmaz, Müjde, et al.
Publicado: (2022)

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
por: Brink, Mirian, et al.
Publicado: (2021)

No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study
por: Geerdes, Emma E., et al.
Publicado: (2023)

Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019
por: Maas, Carolien C.H.M., et al.
Publicado: (2023)

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018
por: Maas, Carolien C. H. M., et al.
Publicado: (2021)

The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands
por: Dinmohamed, Avinash G., et al.
Publicado: (2020)

Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989–2018
por: van der Straten, Lina, et al.
Publicado: (2022)

Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival
por: Gangat, Naseema, et al.
Publicado: (2023)

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
por: Wester, Ruth, et al.
Publicado: (2022)

Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis
por: Li, B, et al.
Publicado: (2016)

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study
por: Dinnessen, Manette A.W., et al.
Publicado: (2020)

Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands
por: Dinmohamed, Avinash G, et al.
Publicado: (2020)

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

Characterizing the Bone Marrow Environment in Advanced-Stage Myelofibrosis during Ruxolitinib Treatment Using PET/CT and MRI: A Pilot Study
por: Slot, Stefanie, et al.
Publicado: (2023)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

Liver function test abnormalities and their clinical relevance in primary myelofibrosis
por: Barraco, D, et al.
Publicado: (2017)

Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population‐based study during 1990–2015
por: Reedijk, Ardine M. J., et al.
Publicado: (2020)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

S205: INHIBITING THE ALARMIN-DRIVEN HEMATOPOIESIS-STROMAL CELLS CROSSTALK IN PRIMARY MYELOFIBROSIS AMELIORATES BONE MARROW FIBROSIS
por: Gleitz, Hélène, et al.
Publicado: (2023)

Fibrocytes in primary myelofibrosis
por: Shimoda, Kazuya, et al.
Publicado: (2021)

Elevated RIPK3 correlates with disease burden in myelofibrosis
por: Dill, Veronika, et al.
Publicado: (2022)

A Rare Case of Primary Myelofibrosis With a Solitary 1q Triplication
por: Kim, Jin-Hong, et al.
Publicado: (2020)

Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia: treatment of two different diseases with one agent
por: Burgstaller, S, et al.
Publicado: (2011)

Primary Hypertrophic Osteoarthropathy With Myelofibrosis
por: Yousaf, Muhammad, et al.
Publicado: (2022)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j0nui4vtf5n8fl1gd5rqpqd719